Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus AD chemotherapy for first-line advanced UPS
ChiCTR2100049974Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, doxorubicin and dacarbazine in Malignant Fibrous Histiocytoma (MFH), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: objective response rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
camrelizumabdoxorubicindacarbazine
03
Conditions
Malignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on ChiCTR2100049974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049974.